Rigel Pharmaceuticals, Inc. RIGL
42.49 USD +0.44 (+1.04%)
Nov 10, 2026, 11:13 AM EST
41.91 Day range 43.00
24.95 52-week range 52.61
- YTD
- -0.80%
- 1 year
- +22.97%
News
seekingalpha.com Rigel Pharmaceuticals: Top-Line Momentum Meets Margin Compression In Q3 Rigel Pharmaceuticals shows strong top-line growth but faces margin compression, with Q3 revenues up 16.5% year-over-year and net income down 52.7%. VEPPANU's launch is promising, generating $6.6…
benzinga.com Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $86 Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $83 to $86.
benzinga.com Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $47 Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $43 to $47.
seekingalpha.com Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call Transcript Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call Transcript
benzinga.com Rigel Pharmaceuticals Q3 2026 Earnings Call Transcript Rigel Pharmaceuticals (NASDAQ:RIGL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…- benzinga.com Rigel Pharmaceuticals Raises FY2026 Sales Guidance from $285.000M-$295.000M to $290.000M-$295.000M vs $305.733M Est Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2026 sales outlook from $285.000 million-$295.000 million to $290.000 million-$295.000 million vs $305.733 million estimate.
prnewswire.com Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition Oral presentation to feature updated data from the dose escalation and dose expansion phases of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed…
benzinga.com HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $85 price target.
benzinga.com Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49 Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $40 to $49.
benzinga.com HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $85 HC Wainwright & Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $57 to $85.
benzinga.com Rigel Pharmaceuticals' VEPPANU For Adults With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Estrogen Receptor 1-Mutated Advanced Or Metastatic Breast Cancer Now Available Via U.S. Prescription VEPPANU is the first and only FDA-approved PROteolysis TArgeting Chimera (PROTAC). PROTACs are a new class of heterobifunctional protein degraders designed to harness the body's natural machinery to…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their…
benzinga.com Rigel Pharmaceuticals Raises FY2026 Sales Guidance from $275.000M-$290.000M to $285.000M-$295.000M vs $308.461M Est Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2026 sales outlook from $275.000 million-$290.000 million to $285.000 million-$295.000 million vs $308.461 million estimate.
benzinga.com Rigel Pharmaceuticals Q2 EPS $0.88 Beats $0.62 Estimate, Sales $78.700M Beat $69.463M Estimate Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.62 by 41.94 percent. This is a 73.17 percent decrease over earnings…- benzinga.com Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The Agreement Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.- benzinga.com Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $81 Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $69 to $81.
benzinga.com These Analysts Increase Their Forecasts On Arvinas After Q1 Results Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE)…
benzinga.com Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.
benzinga.com Arvinas, Pfizer Strike Up To $405M VEPPANU Licensing Deal With Rigel Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. (NYSE:PFE) have entered into a license agreement with Rigel…- benzinga.com Rigel to Pay $85M Upfront for FDA-Approved VEPPANU; Potential $320M in Milestones Ahead Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that it has entered into an exclusive, global license…
- benzinga.com Citigroup Maintains Buy on Rigel Pharmaceuticals, Lowers Price Target to $69 Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and lowers the price target from $71 to $69.
- benzinga.com Rigel Pharmaceuticals Affirms FY2026 Sales Guidance of $275.000M-$290.000M vs $284.068M Est Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 million to $275.000 million-$290.000 million vs $284.068 million estimate.
benzinga.com Rigel Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - benzinga.com Rigel Pharmaceuticals Q1 EPS $0.44 Misses $0.76 Estimate, Sales $58.800M Miss $62.392M Estimate Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.76 by 42.11 percent. This is a 30.16 percent decrease over…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Eli Lilly To Terminate Rigel Collaboration On RIPK1 Inhibitor Ocadusertib Effective June 15, 2026; Does Not Expect Future Milestones Or Royalties Under Agreement After Termination Termination of a Material Definitive Agreement.On April 16, 2026, Rigel Pharmaceuticals, Inc. ("Rigel") received written notice from Eli Lilly and Company ("Lilly") of Lilly's election to terminate…
- benzinga.com FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda
- benzinga.com Rigel Pharmaceuticals Publishes Final Data From Phase 1/2 ARROW Trial Of Pralsetinib To Treat Metastatic Rearranged During Transfection Fusion-Positive Non-Small Cell Lung Cancer Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase 1/2…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Nasdaq Surges Over 1%; ISM Services PMI Tops Views U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd, Latham Group Inc, and Can Fite Biopharma surge.- benzinga.com Rigel Pharmaceuticals Affirms FY2026 Sales Guidance of $275.000M-$290.000M Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 million to $275.000 million-$290.000 million.
benzinga.com Earnings Summary: Rigel Pharmaceuticals Q4 - benzinga.com Rigel Pharmaceuticals Q4 Adj. EPS $1.12 Misses $1.25 Estimate, Sales $69.802M Beat $68.701M Estimate Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.12 per share which missed the analyst consensus estimate of $1.25 by 10.18 percent. This is a 40 percent increase over earnings…
- benzinga.com Earnings Scheduled For March 3, 2026
benzinga.com A Preview Of Rigel Pharmaceuticals's Earnings - benzinga.com Rigel Reports Preliminary Q4 2025 Revenue Of $69.8M; Guides 2026 Revenue Of $275M-$290M Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million and contract revenues of $4.4 millionIn the dose escalation phase of the…
- benzinga.com Reported Sunday, Rigel Presents Updated Phase 1b R289 Data In Lower-Risk MDS At ASH 2025, Showing 33% RBC-TI At ≥500 Mg With Favorable Tolerability R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patientsRBC-TI was achieved by 33% (6/18) of…
- benzinga.com Rigel Pharmaceuticals Reports Publication In The Journal Of Hematology & Oncology; 5-Year Data Showing Durable Efficacy And Manageable Safety For REZLIDHIA In R/R mIDH1 AML Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously treated with venetoclax-based…
- benzinga.com Jefferies Upgrades Rigel Pharmaceuticals to Buy, Raises Price Target to $42 Jefferies analyst Eun Yang upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Hold to Buy and raises the price target from $23 to $42.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday - benzinga.com Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $38 Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $32 to $38.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Rigel Pharmaceuticals Raises FY2025 Sales Guidance from $210.000M-$220.000M to $285.000M-$290.000M vs $281.095M Est Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $210.000 million-$220.000 million to $285.000 million-$290.000 million vs $281.095 million estimate.
- benzinga.com Rigel Pharmaceuticals Q3 EPS $1.46 Beats $0.84 Estimate, Sales $69.462M Beat $61.880M Estimate Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of $0.84 by 73.19 percent. This is a 108.57 percent increase over earnings…